Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Pepgen Inc

Clinical trials sponsored by Pepgen Inc, explained in plain language.

PepGen Inc PEPG NASDAQ

Biotechnology company developing peptide-conjugated oligonucleotide therapies for neuromuscular diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Completed 1 Terminated 1

New drug trial for duchenne MD halted early – what we know

Disease control Terminated

This phase 2 study tested a drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be corrected by skipping exon 51. The drug was given by IV infusion to see if it is safe and tolerable. The trial was terminated, so results are limited.

Phase: PHASE2 • Sponsor: PepGen Inc • Aim: Disease control

Last updated Jun 27, 2026 08:01 UTC